Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy
Tanvi Khera1, Daniel Todt1, Koen Vercauteren2, C. Patrick McClure3, Lieven Verhoye2, Ali Farhoudi2, Sabin Bhuju4, Robert Geffers4, Thomas F. Baumert5,6,7, Eike Steinmann1, Philip Meuleman2, Thomas Pietschmann1,8, Richard J.P. Brown1
1Institute of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, A joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Feodor-Lynen-Str. 7, 30625, Hannover, Germany
2Laboratory of Liver Infectious Diseases, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Gent, Belgium
3The School of Life Sciences and the NIHR Nottingham Digestive Diseases Biomedical Research Unit, The University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK
4Genome Analytics, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany
5Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France
6Université de Strasbourg, Strasbourg, France
7Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
8German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Germany
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Antiviral Research
Tập 139
129-137
Thông tin tác giả